These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 3991366

  • 1. Specificity of nucleus accumbens to activities related to cholecystokinins in rats.
    Katsuura G, Itoh S, Hsiao S.
    Peptides; 1985; 6(1):91-6. PubMed ID: 3991366
    [Abstract] [Full Text] [Related]

  • 2. CCK-8 injected into the nucleus accumbens attenuates the supersensitive locomotor response to apomorphine in 6-OHDA and chronic-neuroleptic treated rats.
    Weiss F, Ettenberg A, Koob GF.
    Psychopharmacology (Berl); 1989; 99(3):409-15. PubMed ID: 2574480
    [Abstract] [Full Text] [Related]

  • 3. Altered responding to cholecystokinins and dopaminergic agonists following 6-hydroxydopamine treatment in rats.
    Hsiao S, Katsuura G, Itoh S.
    Behav Neurosci; 1985 Oct; 99(5):853-60. PubMed ID: 3939625
    [Abstract] [Full Text] [Related]

  • 4. Topographical analysis of nucleus accumbens sites at which cholecystokinin potentiates dopamine-induced hyperlocomotion in the rat.
    Crawley JN, Hommer DW, Skirboll LR.
    Brain Res; 1985 Jun 03; 335(2):337-41. PubMed ID: 4005562
    [Abstract] [Full Text] [Related]

  • 5. Cholecystokinin tetrapeptide, proglumide and open-field behavior in rats.
    Hsiao S, Katsuura G, Itoh S.
    Life Sci; 1984 May 28; 34(22):2165-8. PubMed ID: 6727557
    [Abstract] [Full Text] [Related]

  • 6. Behavioral evidence for cholecystokinin modulation of dopamine in the mesolimbic pathway.
    Crawley JH.
    Prog Clin Biol Res; 1985 May 28; 192():131-8. PubMed ID: 4080706
    [Abstract] [Full Text] [Related]

  • 7. Antagonists of central and peripheral behavioral actions of cholecystokinin octapeptide.
    Crawley JN, Stivers JA, Hommer DW, Skirboll LR, Paul SM.
    J Pharmacol Exp Ther; 1986 Feb 28; 236(2):320-30. PubMed ID: 3003339
    [Abstract] [Full Text] [Related]

  • 8. Subtype-selective cholecystokinin receptor antagonists block cholecystokinin modulation of dopamine-mediated behaviors in the rat mesolimbic pathway.
    Crawley JN.
    J Neurosci; 1992 Sep 28; 12(9):3380-91. PubMed ID: 1527584
    [Abstract] [Full Text] [Related]

  • 9. Pharmacological and mechanistic studies of cholecystokinin-facilitated [3H]dopamine efflux from rat nucleus accumbens.
    Vickroy TW, Bianchi BR.
    Neuropeptides; 1989 Jan 28; 13(1):43-50. PubMed ID: 2466220
    [Abstract] [Full Text] [Related]

  • 10. Influence of cholecystokinin on central monoaminergic pathways.
    Widerlöv E, Kalivas PW, Lewis MH, Prange AJ, Breese GR.
    Regul Pept; 1983 May 28; 6(2):99-109. PubMed ID: 6308717
    [Abstract] [Full Text] [Related]

  • 11. The cholecystokinin analogue, caerulein, does not modulate dopamine release or dopamine-induced locomotor activity in the nucleus accumbens of rat.
    Hamilton M, Sheehan MJ, De Belleroche J, Herberg LJ.
    Neurosci Lett; 1984 Jan 27; 44(1):77-82. PubMed ID: 6717857
    [Abstract] [Full Text] [Related]

  • 12. Interactions of cholecystokinin octapeptide and dopamine on nucleus accumbens neurons.
    White FJ, Wang RY.
    Brain Res; 1984 May 21; 300(1):161-6. PubMed ID: 6145498
    [Abstract] [Full Text] [Related]

  • 13. Behavioral effects of cholecystokinin and its related peptides in rats.
    Itoh S, Katsuura G.
    Prog Clin Biol Res; 1985 May 21; 192():139-45. PubMed ID: 2934743
    [Abstract] [Full Text] [Related]

  • 14. Effects of long-term haloperidol treatment on the responsiveness of accumbens neurons to cholecystokinin and dopamine: electrophysiological and radioligand binding studies in the rat.
    Debonnel G, Gaudreau P, Quirion R, de Montigny C.
    J Neurosci; 1990 Feb 21; 10(2):469-78. PubMed ID: 2137531
    [Abstract] [Full Text] [Related]

  • 15. In rats, the behavioral profile of CCK-8 related peptides resembles that of antipsychotic agents.
    Van Ree JM, Gaffori O, De Wied D.
    Eur J Pharmacol; 1983 Sep 16; 93(1-2):63-78. PubMed ID: 6138272
    [Abstract] [Full Text] [Related]

  • 16. Asymmetry in behavioral responses to cholecystokinin microinjected into rat nucleus accumbens and amygdala.
    Belcheva I, Belcheva S, Petkov VV, Petkov VD.
    Neuropharmacology; 1994 Aug 16; 33(8):995-1002. PubMed ID: 7845556
    [Abstract] [Full Text] [Related]

  • 17. Passive avoidance deficit following intracerebroventricular administration of cholecystokinin tetrapeptide amide in rats.
    Katsuura G, Itoh S.
    Peptides; 1986 Aug 16; 7(5):809-14. PubMed ID: 3797342
    [Abstract] [Full Text] [Related]

  • 18. Nucleus accumbens cholecystokinin (CCK) can either attenuate or potentiate amphetamine-induced locomotor activity: evidence for rostral-caudal differences in accumbens CCK function.
    Vaccarino FJ, Rankin J.
    Behav Neurosci; 1989 Aug 16; 103(4):831-6. PubMed ID: 2765186
    [Abstract] [Full Text] [Related]

  • 19. In vivo electrochemical analysis of cholecystokinin-induced inhibition of dopamine release in the nucleus accumbens.
    Lane RF, Blaha CD, Phillips AG.
    Brain Res; 1986 Nov 05; 397(1):200-4. PubMed ID: 3801862
    [Abstract] [Full Text] [Related]

  • 20. The effects of cholecystokinin on the in vivo release of newly synthesized [3H]dopamine from the nucleus accumbens of the rat.
    Voigt MM, Wang RY, Westfall TC.
    J Neurosci; 1985 Oct 05; 5(10):2744-9. PubMed ID: 4045551
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.